Yahoo Search Busca da Web

Resultado da Busca

  1. Há 1 dia · colorectal cancer is now advancing toward the molecular level. 18–20 Personalized therapy is a strategy that in volves FIGURE Kaplan–Meier survival curve of stage and mutation patterns ...

  2. Há 3 dias · The molecular categorization of colon cancer patients remains elusive. Gene set enrichment analysis (GSEA), which investigates the dysregulated genes among tumor and normal samples, has revealed ...

  3. Há 3 dias · Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide 1.Tumor heterogeneity, a hallmark of CRC, has emerged as a critical factor ...

  4. Há 3 dias · Cancer Res 80:2969-2974, 2020 2. Tariq K, Ghias K: Colorectal cancer carcinogenesis: A review of mechanisms. Cancer Biol Med 13:120-135, 2016 3. Neumann J, Zeindl-Eberhart E, Kirchner T, et al: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205:858-862, 2009 4.

  5. Há 1 dia · In the realm of colorectal cancer treatment, current treatment options for colorectal cancer encompass surgery, radiotherapy, chemotherapy, and targeted therapy. 2 Among these, targeted therapy has made significant progress in the treatment of relapsed or refractory cases. 3 Additionally, a distinct molecular subtype of colorectal cancer has been identified, characterized by high ...

  6. Há 3 dias · KRAS mutations contribute substantially to the overall colorectal cancer burden and have long been a focus of drug development efforts. After a lengthy preclinical road, KRAS inhibition via the G12C allele has finally become a therapeutic reality. Unlike in NSCLC, early studies of KRAS inhibitors in CRC struggled to demonstrate single agent activity. Investigation into these tissue-specific ...

  7. Há 2 dias · Colorectal cancer (CRC) is the third most common type of cancer and the second leading cancer-related death worldwide . Many studies have attempted to identify circulating proteins as biomarkers in CRC patients, including biomarkers for the early detection of CRC [ 4 , 5 ], prognosis [ 6 , 7 ], treatment response [ 7 ], regional tumor localization [ 6 ], and disease dissemination [ 6 ].